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Abstract
Background: The assessment of fear of recurrence (FCR) is crucial for understanding an important psychological
state in patients diagnosed and treated for cancer. The study aim was to determine psychometric details of a seven
question self-report scale (FCR7) and a short form (FCR4) based upon items already used in various extensive
measures of FCR.
Methods: Two consecutive samples of patients (breast and colorectal) were recruited from a single specialist cancer
centre. The survey instrument contained the FCR7 items, Hospital Anxiety and Depression Scale (HADS), and
demographic details. Clinical information was obtained from patient hospital records. Statistical analyses were performed
using classical test and item response theory approaches, to demonstrate unidimensional factor structure and testing key
parameters. Construct validity was inspected through nomological and theoretical prediction.
Results: Internal consistency was demonstrated by alpha coefficients (FCR4: 0.93 and FCR7: 0.92). Both scales (FCR7 &
FCR4) were associated with the HADs subscales as predicted. Patients who experienced chemotherapy, minor aches/
pains, thought avoidance of cancer and high cancer risk belief were more fearful. Detailed inspection of item responses
profile provided some support for measurement properties of scales.
Conclusion: The internal consistency, and pattern of key associations and discriminability indices provided positive
psychometric evidence for these scales. The brief measures of FCR may be considered for audit, screening or routine use
in clinical service and research investigations.
Background
Fears of cancer recurrence (FCR), has recently been de-
fined by an expert panel in a three-wave Delphi study, as
‘fear, worry, or concern relating to the possibility that
cancer will come back or progress ‘. There is substantial
variation in the experience of this fear with a small per-
centage of patients who report no fears of this nature at
all to those who state a specific concern of the cancer
returning requiring specialist intervention [1].
Numerous attempts have been made to design mea-
sures of FCR and a review has listed those questionnaires.
Authors of the review recommend further research to as-
sist this process of development and refinement [2].
Thewes et al. argued that the lack of an accepted
definition of FCR had resulted in many measures being
developed. Simonelli et al. [3] has highlighted a number
of issues requiring attention: 1) single point designs, 2)
over-reliance on breast cancer survivors, 3) lack of cut-off
point, 4) lack of conceptualisation of FCR, and 5) cross-
cultural validity.
The assessment of FCR has taken a number of ap-
proaches [2]. They can be divided into two main types, in-
cluding single item or multi-item scales. A single item scale
is easy to administer, can be applied on multiple occasions,
but psychometrically can be limited in measurement per-
formance when investigators have attempted to determine
some key parameters (e.g. reliability). For instance, single-
item assessments of depression have been shown to have
some serious shortcomings [4]. Multi-item scales have the
benefit of assessing a variety of qualities or features of FCR
[5]. However, they can be burdensome to complete, time-
consuming and challenging to score and interpret. Costa et
* Correspondence: gmh4@st-andrews.ac.uk
1School of Medicine, University of St Andrews, St Andrews, Fife, Scotland
2Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Humphris et al. Health and Quality of Life Outcomes  (2018) 16:30 
DOI 10.1186/s12955-018-0850-x
al. makes the case that FCR is best assessed using a single
dimensional design consisting of a small set of items [6].
The rationale we believe that is being supported by Costa
et al. is to identify the key area to be accurately measured
and then follow up through further assessment with associ-
ated features. These areas can be assessed through, either
specific packets of items in a further questionnaire, or a
structured clinical interview. The short uni-dimensional
measure can then be considered initially as a screening in-
strument for additional follow-up and enquiry.
The Concerns About Recurrence Questionnaire (CAR-
Q) has been investigated as a possible brief scale for FCR
[7]. It has been constructed as a 5 item scale that questions
the respondent about frequency, intrusiveness and degrees
of distress. An item of risk perception is also included.
There is a translation into Danish as well as English there-
fore promoting a cross-cultural dimension. The authors
used classical test theory (CTT) in addition to single par-
ameter models (Item Response Models, IRT) to estimate
difficulty (referred to also as ‘location’ or ‘severity’ across
the latent construct). The CAR-Q was developed specific-
ally for breast cancer. Our group has considered bringing
together a scale that will function well across numerous
cancer sites. This would save substantial effort and also en-
able comparisons across sites. The CAR-Q is perhaps the
closest to what we would regard as a scale that has been
studied in some detail psychometrically. There are some
satisfactory features of this scale and the work by the origi-
nators is carefully reported. Their IRT results on further in-
spection do show some extensive local dependence issues
which they do state in their 2015 article will need address-
ing and some items rewording. They state that CAR-Q-4
(the 4 item version) perhaps is the most reliable but admit
that the 4 item English version did not fit the Rasch model
and did not report the fit for the Danish sample saying that
‘modelling’ was not possible with the 4-item scale. Was this
a convergence problem? This is not elucidated. The model-
ling also was rejected for this Danish 3 item version. Our
interpretation suggests that there are some unsatisfactory
psychometric qualities to this scale. Furthermore, no brief
FCR scale has adopted the more flexible two parameter
graded response model IRT approach. The advantage of
this later approach is that both item discrimination (slope)
as well as difficulty/severity (location) are estimated
simultaneously.
The scale that we have developed and employed in a var-
iety of centres in the UK (over 70 NHS units) [8] is based
upon a set of 7 questions that have been selected from ex-
tant measures within the literature to assess directly FCR.
The FCR4 contains the first four items of the FCR7. That is
the FCR7 is the FCR4 with the addition of 3 additional
items. The Flesch readability index for the FCR7 is 60.2 and
the shorter 4 item version (FCR4) is 55.1, equivalent to
‘Plain English, easily understood by 13- to 15-year-old
students’. Although used relatively extensively in the UK
there are important considerations about the multi-item
measure and its psychometric characteristics.
This paper reports on the evaluation of a 7 item FCR
scale (FCR7) and that has already been presented in a
sample of head and neck cancer patients in the North-
west of England [9]. Our belief is that the item wording
taken from many of the available measures would make
suitable short screening instruments for routine clinical
service use. Our rationale was to produce a patient accept-
able and psychometrically sound short FCR scale. The
four item version (FCR4) for example has been used in a
major study with patients with head and neck cancer in
the UK [10] and percentile norms have been presented
(with confidence intervals) for clinicians to include in the
patient records. The novel aspect of this paper includes
the evidence obtained from CTT and IRT analytical ap-
proaches to both the four and seven item forms.
Aim
To present two versions (4 and 7 items) of screening as-
sessments for FCR and describe their psychometric fea-
tures. The objectives are:
1. To present the selection of items comprising the
measures and item wording;
2. To outline psychometric features based upon
Classical Test Theory (CTT);
3. To summarize Item Response Theory (IRT)
estimates for scale items;
4. To present recommendations for version choice and
future research.
Methods
Sample
The setting for the study was the Edinburgh Cancer
Centre where a tertiary regional service is provided with
full radiotherapy, chemotherapy and surgery treatment
modalities available. The Breast Cancer and Colorectal
Units and their Multi-Disciplinary Teams gave approval
for recruiting their patients. The participants consisted of
consecutive patients attending the out-patient clinics of
the two Units. Exclusion criteria were: serious mental ill-
ness, non-English speaking, treatment for recurrent can-
cer and terminally ill. During the data collection of
5 months there were 482 breast and 116 colorectal cancer
patients available for recruitment. As some patients were
undergoing further tests, the total eligible for written con-
tact was 324 and 101 respectively which enabled a total
pool of 425 patients (71% of 598).
Measures
The FCR scale was based on examining past measures of
this construct with a focus on anxiety or fear. Sixteen
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items were considered as candidates for the short ver-
sions. Through a consensus approach of cycling through
these items between the authors and also piloting them
with patients at the ECC to examine reactions to item
wording we selected the final item pool. The four ques-
tion scale (FCR4) was designed to feature anxiety, worry
and strong feelings coupled with return of the disease
(Q1–4). The longer seven question scale, to some extent
was a compromise somewhat extending the item pool by
featuring two items on the cognitive processing compo-
nent that anxiety, fears or worries may interfere or po-
tentially distort thoughts about cancer returning, Q5
and Q7. Finally, an item describing a behavioural re-
sponse to FCR was included, Q6. Our approach for the
FCR7 was to introduce additional items that were not
simply variations of the first 4 items comprising the
FCR4. One of the issues identified by patients when
completing original formulations was the repetitive na-
ture of some of the wording employed. Hence we intro-
duced items that were worded with additional content
(cognitive and behavioural) but possibly with substantial
association with the core uni-dimensional construct. See
Additional file 1: FCR7 for copy of Scale. The empirical
data generated would enable inspection of the veracity
of this approach.
To assist with validating the FCR measures (FCR4 and
FCR7) a number of additional hypothetical constructs
were assessed and their relationships tested using the
construct validation approach outlined by Streiner and
Norman [11]. This approach subsumes other forms of
validity [12]. The Hospital Anxiety and Depression Scale
(HADS) was administered [13]. We predicted that the
FCR scales will be significantly related to anxiety and
somewhat less so with depression, based upon a prior
review [1], and adopting the two-factor model of the
HADS measure [14]. In addition, a short number of sin-
gle question items, were also included to assess the rela-
tionship with the total FCR scores. We included three
items with 5 category ordinal rating scales ranging from
‘not at all’ to ‘all the time’. We deliberately chose
statements that reflected some key areas known to be
associated according to the three major components of
Lee-Jones et al. model [15] of FCR derived from
Leventhal’s self-regulation model (SRM), namely: repre-
sentation of symptoms (‘Minor aches and pains remind
me of cancer’), coping strategies (‘I just try to ignore
feelings about the cancer returning’), and appraisal (‘In
your opinion, what is your risk of having cancer recur-
rence?’). We expected the FCR scales to be positively as-
sociated with these components. We recognised that
multi-item-scales are preferable to single items for asses-
sing each of these components. However the inclusion
of these clear statements reflecting the SRM would en-
able supportive evidence to be compiled. For example, a
hypothesis was made that the avoidance coping strategy
may not be as closely related to FCR as respondents
may defer the process of accessing either, their fears, or
admission of using avoidance [16, 17].
Finally, patients who undergo mixed treatment proto-
cols, and therefore believe their condition to be more
complex and difficult to irradicate would tend to have
raised FCR levels [1]. Recently, this has been confirmed
in meta-analyses conducted by our group [18, 19].
Statistical analysis
Data were analysed using SPSS v22 (IBM Corp.) for de-
scriptive analyses, and reliability analysis conducted
with FACTOR [20]. Initially, the scales were factor ana-
lysed (principal factor method) [21] and Horn’s parallel
analysis was run to determine the factorial structure
[22]. Relationships between the total scores (FCR7 and
FCR4) obtained from summing the items (without fac-
tor weights) were examined visually through scatter-
grams, polynomial smoothing graphics (STATA v14,
StatCorp, College Station, Texas), and Pearson correl-
ation coefficients. Spearman’s rho rank correlations
were employed with the single question rating scale
items to test association with the FCR4 and FCR7
scales. Alpha was set to 0.05 (two-sided) throughout.
The Item Response Theory (IRT) ‘grm’ procedure
within STATA v14 was applied. This enables
discriminability and difficulty parameters using max-
imum likelihood estimation to be produced simul-
taneously and graphically presented. The approach
provides a much more intensive inspection of the
performance of the FCR4 and FCR7 items than the
more conventional CTT approach. The two assump-
tions are made when using IRT are unidimensionality
and local item independence. The first assumption is
easily tested by exploratory factor analysis and the
examination of eigenvalues to assess the fit of a sin-
gle latent construct of FCR. The second assumption
is inferred from examination of the item wording.
Ethical approval
The study was introduced to potential participants
through a participant information sheet (PIS) and
written consent obtained. A research assistant iden-
tified potential participants by reading through
notes of patients planned for BT/CRC clinic visits.
A letter then was sent out signed by their clinician
inviting them to participate in the study, including a
patient information sheet. The potential participant
was met by the research assistant at clinic appoint-
ment, and they were given the opportunity to ask
questions, and if they agreed to participate, they
signed a consent form and answered the question-
naire. Patients were able to withdraw at any time,
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according to conventional ethical guidelines. The
study was approved by NRES (07/S1103/27) and
NHS Lothian R&D.
Results
Persons who had received treatment at the tertiary cancer
centre with disease of the breast (N = 206; mean age = 63)
or colorectal cancer (N = 53 mean age = 67) attended the
nurse-led follow-up clinics to complete questionnaire.
Hence, from the total pool of eligible patients available we
attained a 61% response rate (259/425). The frequency
breakdown of demographics, cancer severity and details of
tumour (node involvement and margins) are presented
(Table 1). The majority of patients were females (226 vs 33)
although within the colorectal group 60% were men. There
was reasonable representation across age range. Patients
aged 35 to 49 years were relatively few 21/259 (8%). About
10% of the sample were single (26/259) and 61% married
(157/259). Educational level was mixed and the large ma-
jority (79%) were resident in owner-occupied accommoda-
tion. The cancer staging between sites was very different.
Patients were characterised by low severity in breast cancer
and advanced in colorectal cancer. Node involvement was
comparable at approximately 2/3rds across sites. Margins
tended to be clear. Patients with colorectal cancer, however
had margins that were difficult to establish.
The responses to the FCR4 (and FCR7) questions are
summarised across cancer sites as mean levels for individ-
ual items and total scores. The 60th and 90th percentile
values for both scales across cancer sites are also pre-
sented (Table 2). Discussions had been conducted infor-
mally with clinicians (oncologists, surgeons and specialist
nursing staff ) who gave opinions seeking identification of
their patients who scored at a moderately high level which
was determined to be greater than the average. Hence a
60th percentile was regarded as a pragmatic level to re-
port. In addition those clinicians who requested an esti-
mated level of high FCR stated that the top one in ten
scorers would be helpful to identify. Therefore pragmatic
considerations that clinicians favoured drove our choice of
percentile. Another approach was to produce detailed ta-
bles of deciles that may produce extensive but overwhelm-
ing information for the non-specialist psychometrician.
This recruitment level for patients with colorectal cancer
was lower than anticipated (N = 53). A statistical amend-
ment to our analysis strategy was included as a conse-
quence. We introduced a bootstrapping procedure.
95%CIs for the percentile range was calculated to assess
precision of the two percentiles scores for both FCR4 and
FCR7, by applying a bootstrap consisting of 1000 samples.
The scores at each percentile level across the two sites
were similar, taking into account the confidence interval
for the colorectal cancer patients, that is 10 (FCR4) and
15 (FCR7) for the 60th percentile and 15 (FCR4) and 27
(FCR7) for the 90th percentile. The percent ‘zero’ scorers,
that is, patients who rated themselves with the minimum
score on FCR was 9% for the FCR4 and 4% for the FCR7
Table 1 Demographics of breast and colorectal samples
Cancer Site
Breast (N = 206*) Colorectal (N = 53*)
Gender N %** N %**
Female 205 99 21 40
Male 1 1 32 60
Age
35 to 49 19 9 2 4
50 to 59 57 28 13 25
60 to 69 84 41 17 32
70+ 46 22 21 40
Marital Status
Married 121 59 36 68
Divorced 19 9 5 9
Widowed 34 17 6 11
With partner 6 3 2 4
Single 22 11 4 8
Education
No formal qualification 64 31 20 20
GCSE/O Levels 46 22 10 19
A Levels/Equivalent 38 18 4 8
Univ Degree 45 22 14 26
Higher Univ Degree 9 4 5 9
Accommodation
Owner Occupier 164 80 40 76
Rented/Council 27 13 10 19
Private landlord 6 3 0 0
Other 4 2 2 4
Cancer Staginga
I 51 54 3 6
II 33 35 5 10
III 6 6 33 67
IV 3 3 8 16
Node Involvement
Yes 49 25 16 32
No 130 66 34 68
Unknown 17 9 0 0
Cancer Margins
Clear 105 54 16 32
Not Clear 15 8 3 6
Unknown 76 39 31 62
*some missing participant responses as indicated; a. Missing data due to
staging not available
**percentages rounded to integer level, therefore sum not always 100%
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scale. The lower percentage of ‘zero’ scorers with the
FCR7 scale is due to there being 7 opportunities rather
than 4 with the FCR4 to indicate a rating on at least one
item greater than the minimum level.
Psychometric properties CTT: Structure and internal
consistency
To satisfy the second aim, the investigators began by
conducting exploratory factor analyses using parallel
analysis to derive simulated eigenvalues from random
samples for comparing with the observed data was con-
ducted. The factor loadings for all 7 items were all high
(> 0.7) with the exception of Question 6 which was 0.45.
The Kaiser-Meyer-Olkin test (indicates if sufficient com-
mon variance exists to merit factor analysis) gave satis-
factory high values of 0.86 and 0.92 for FRC4 and FCR7,
respectively [21]. The factor analyses demonstrated sin-
gle factor structures (eigenvalue for first factor = 3.3 and
4.8, for FRC4 and FCR7 respectively), which is equiva-
lent to three and nearly 5 times the average amount of
variance contained within the single factors of FCR4 and
FCR7 as the rest of each of the covariance matrices. Ei-
genvalues derived from the bootstrapping procedure,
that selects multiple random samples (n = 1000) from
the original data set, showed that 2 and 4 factors (FCR4
and FCR7 respectively) would have been selected (eigen-
values ranging greater than 1) if the conventional, but
now criticised unity criteria [23] for setting the number
of factors had been recognised (Fig. 1a and b). We ran a
confirmatory factor analysis to test the invariance of the
unidimensional model across cancer sites and the chi
square test returned a low values for FCR4 (chi-sq. =
2.97, df3, p = 0.39) and FCR7 (chi-sq. = 4.14, df6, p =
0.66) demonstrating that the measurement properties
were not sufficiently different across sites to warrant a
change of weighting of the items [24].
The reliability coefficients were acceptable for both
scale versions (Table 3), that is above 0.9. It was interest-
ing that even restricting the measure to the first 3 items
of the FCR4 returned a Cronbach’s alpha of 0.92 for the
whole sample.
Psychometric properties CTT: Validity
Associations of FCR4 and FCR7 total scores with anxiety
and depression subscales scores of the HADS were sig-
nificant as calculated by Pearson’s product-moment cor-
relation coefficient (Table 4). The comparison between
the correlations of FCR4 and FCR7 with anxiety (≈ 0.66)
and depression (≈ 0.38) showed that fears of recurrence
are associated more strongly with anxiety than
Table 2 Verbatim items including origin, frequencies, means (SDs) for breast and colorectal patient samples, with 60th and 90th
percentiles, and percent ‘zero’ scorers
Question Number and Text FCR4 FCR7 Breast (n = 206) Colorectal (n = 53) Total (n = 259)
m (sd) m (sd) m (sd)
Q1: I am afraid that my cancer may recur1 Fcr1 Fcr1 2.55 (1.01) 2.26 (0.98) 2.49 (1.01)
Q2: I am worried or anxious about the possibility of cancer recurrence2 Fcr2 Fcr2 2.31 (1.00) 2.11 (1.05) 2.27 (1.01)
Q3: How often have you worried about the possibility of getting cancer again3 Fcr3 Fcr3 2.74 (0.90) 2.51 (1.01) 2.69 (0.93)
Q4: I get waves of strong feelings about the cancer coming back4 Fcr4 Fcr4 1.95 (1.08) 1.85 (1.08) 1.93 (1.08)
Q5: I think about the cancer returning when I didn’t mean to4 Fcr5 1.97 (0.92) 1.77 (0.85) 1.93 (0.91)
Q6: I examine myself to see if I have physical signs of cancer2 Fcr6 2.84 (1.04) 2.06 (1.13) 2.68 (1.10)
Q7: To what extent does worry about getting cancer again spill over or intrude
on your thoughts and activities3
Fcr7 2.61 (2.49) 2.34 (2.41) 2.56 (2.47)
Total FCR4 9.54 (3.60) 8.74 (3.79) 9.37 (3.65)
60th percentile 10 9a 10
90th percentile 15 16a 15
Total FCR7 16.96 (6.88) 14.91 (7.33) 16.54 (7.01)
60th percentile 17 16b 17
90th percentile 27 28b 27
‘Zero’ scorers
FCR4 percent: N 7%, 15 15%, 8 9%, 23
FCR7 percent: N 2%, 5 8%, 4 4%, 9
aConfidence interval around point estimate ranges 5 units (bootstrap)
bConfidence interval around point estimate ranges 8 units (bootstrap)
1From Concern about Recurrence Scale [32]
2From Fears of Cancer Recurrence Inventory [27]
3From Worry of Cancer Scale [34]
4From FORPSYCH study [35]
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depression (difference in correlations: z ≈ 4.5, p <
0.0001). The scattergram of FCR7 total values with the
HADS Anxiety subscale shows a close linear relationship
as confirmed by the close correspondence of the polyno-
mial smoothed line and the summary Ordinary Least
Square fitted line (Fig. 2). The HADS subscale Mean
(SD) score for anxiety was 4.15 (3.37) n = 227 for those
below the cut-off (15) on the FCR4 and 10.56 (3.84) n =
32 at or above cut-off (t = 9.91, df257, p < .0001). The
equivalent HADS Anxiety values at the cut-off (27) for
FCR7 was 4.17 (3.30) n = 232 and 11.56 (3.60) n = 27
(t = 10.90, df257, p < .0001).
Associations with related constructs that are central to
the modified SRM of Lee-Jones et al. (1997) [15]
Spearman rho correlation coefficients between the single
item questions and FCR4 and FCR7 to test construct val-
idity all showed strong associations as predicted (Table 5).
Relatively smaller coefficients were found with the coping
strategy of ‘ignore feelings about the cancer returning’.
a
b
Fig. 1 Exploratory Factor analysis using Parallel Analysis (a) FCR4 (b) FCR7
Table 3 Psychometrics from exploratory factor analysis and
reliability
FCR4 FCR7
Factor loadings (EFA)
Q1 0.91 0.88
Q2 0.93 0.91
Q3 0.91 0.89
Q4 0.88 0.88
Q5 – 0.80
Q6 – 0.52
Q7 – 0.85
Kaiser-Meyer-Olkin Measure of
Sampling Adequacy
0.859 0.920
Internal consistency
Cronbach’s
alpha (α)
0.93 0.92
(95%CI) (0.91, 0.94) (0.90, 0.94)
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Influence of past treatment (Rx and CRx)
Patients who had radiotherapy in their primary treatment
protocol were relatively more fearful on both measures
compared with patients who did not receive radiotherapy,
but these mean differences were not significant (p = >
0.30). Chemotherapy treatment was associated with in-
creased FCR (p = 0.006) compared to those not receiving
chemotherapy equivalent to approximately an effect size
of 0.4 (Table 6).
Psychometric properties IRT
The IRT assumption of unidimensionality was tested and
shown by the CFA results presented already, and also by
calculating the ratio of the first to second eigenvalue being
greater than 4. The ratios for the FCR4 and FCR7 were
10.7 and 6.2 respectively. The second IRT assumption of
local independence of item pairs was regarded as met as
each item was worded differently. Each item invited respon-
dents to reflect different aspects of the experience of FCR.
Hence, the two parameter model was applied and fitted the
responses to all items relatively well as shown by the dis-
criminability coefficients (Table 7). All coefficients for the
FCR4 items were very close or above 4, that is they were
above 1.7 (noted as ‘very high’ according to the criteria of
Baker) [25]. The addition of three items (‘fcr5’ to ‘fcr7’) also
give significant coefficient levels but the ‘fcr6’ item returned
a level of 0.93, which was noted as ‘moderate’ according to
the Baker criteria. The item difficulty levels (also known as
severity or location levels) along the latent construct were
all showing significant fit for each category of the rating
scales with two exceptions in the items ‘fcr1’ and ‘fcr4’
(Table 7). The average item SEs for the difficulty (location
or severity) coefficients was 0.162 (and none of the averages
for each item were above recommended level of 0.35) [26].
The test characteristic curves for both versions (FCR4 and
FCR7) demonstrate that 95% of the sample answer within a
reasonable full range of scores (Fig. 3). That is the range of
values for FCR4 is between scale scores of 4 and 17,
whereas the FCR7 effective range is 7 to 32. For detailed
item information the reader is invited to see the Additional
file 2: IRT supplementary.
Discussion
In this study we set out to evaluate low patient burden
questionnaires to assess FCR. Some classical psychometric
analyses (CTT) [27] were employed to assess the ability of
Table 4 Pearson Correlation matrices for nomological construct validity check
Pearson Correlation Coefficients
mean SD FCR4 FCR7 HADS: Anxiety Sub-scale HADS: Depression Sub-scale
FCR4 9.37 3.65 1 .954** .648** .360**
FCR7 16.54 7.01 1 .678** .404**
HADS: Anxiety Sub-scale 4.94 4.02 1 .610**
HADS: Depression Sub-scale 2.30 2.58 1
**p < 0.01 (2-tailed); N = 259
Fig. 2 Fear of recurrence scale (7 items) and HADS Anxiety sub-scale scatterplot with polynomial smoothing and OLS linear regression line fits
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the items to reflect patients’ recurrence fears in patients
attending out-patient clinics having been treated for either
breast or colorectal cancer. Of importance was the ability
of the measures to detect ‘moderate’ to ‘high’ levels of
FCR defined by the percentile points of the 60th and 90th
percentiles. Percentile range for patients with colorectal
cancer was wide due to small sample size, however the
percentile value was well within the range for the patient
counterparts with breast cancer. The percentile points
(60th and 90th) were chosen from a pragmatic view to as-
sist clinicians to identify where they might consider to in-
vite patients to explore FCR (moderate level) or consider
providing more formal support (high level). The signifi-
cance of the 60th and 90th percentile is to act as indica-
tors for clinical team members to enable them to alert
themselves when patients score above these values in their
outpatient clinics. We suggest that the 60th percentile
would be a level that the clinical team might consider
broaching the subject of FCR with the patient to provide
some psycho-educational support. There were no statis-
tical differences between item means and total scores
(FCR4 and FCR7) across cancer sites. The 90th percentile
might again be used as a trigger to offer not only regular
support but possibly some therapeutic intervention. These
scales therefore may assist clinical teams in designing
programmes for stepped care for persons moving through
their treatment protocols and outpatients [28].
Psychometric properties CTT
The exploraty factor analyses on both FCR4 and FCR7
demonstrated clearly that both scales were uni-dimensional
in structure as shown by the large eigenvalue for the first
factor on both versions. A close inspection of the factor
loadings indicates good correspondence with the latent fac-
tor. A possible exception to this was Q6 (self-examination)
with a loading of 0.52. Overall we consider there is suffi-
cient evidence from this initial analysis to support a unidi-
mensional structure for both scales.
The non-significance result to test cancer site invariance
of the factor loadings provided some limited evidence of no
appreciable difference of measurement structure for both
versions (FCR4 and FCR7) across cancer sites. Larger sam-
ple sizes for each cancer site would give more robust results.
The internal consistency, as assessed by Cronbach al-
phas, for both scales was above 0.92. The lower bound of
the 95% confidence interval was reassuringly above the 0.9
level. These high values for relatively short scales are help-
ful to clinical teams and researchers wishing to include an
assessment for FCR. The burden on patients is low, read-
ability is acceptable, and there were no missing responses
to the items and little, if any, negative reaction of patients
to an invitation to complete the 7 item scale.
Further research with other samples, languages and
cancer sites are recommended to replicate these results.
Psychometric properties CTT: Validity
Associations with HADS anxiety and depression were
confirmed and are consistent with previous reports in
reviews and FCR surveys [1, 29].
The linear relationship with anxiety is convincing
when examining the scattergram presentation and com-
paring the polynomial smoothed curve and the ‘ordinary
least squares’ regression summary line. The levels of
anxiety and depression are very similar to those reported
in a mixed cancer sample (n = 60) from Quebec [30].
The HADS anxiety subscale scores between groups sep-
arated by the cut-offs on both FCR4 And FCR7, sug-
gested by the ROC analyses (contact author for details),
showed a greater effect size (1.87) in comparison to the
Canadian study and its comparison between ‘clinical’
and ‘non-clinical’ groups (0.86).
The rank correlations between three of the fundamen-
tal constructs in the SRM of Leventhal [31], as formu-
lated in reference to FCR [15], namely: Symptoms,
Coping strategy and Risk of recurrence was reassuring.
As predicted the denial of feelings strategy was the
weaker of the associations presented, possibly reflecting
the process of denial as a hidden activity for respondents
Table 5 Spearman Correlations of self-reported Symptoms,
Coping strategies and Risk beliefs with FCR4 and FCR7
Construct
validity Item
FCR4 FCR7
Symptoms
‘Minor aches and pains remind me of
cancer’
.629* .631
Coping Strategy
‘I just try to ignore feelings about the
cancer returning’
.290 .283
Risk of Recurrence
‘In your opinion, what is your risk of
having cancer recurrence?’
.569 .567
*All coefficients (Spearman’s rho) p < 0.001
Table 6 Past treatment history related to FCR4 and FCR7
total scores
Radiotherapy Chemotherapy
FCR4 FCR7 FCR4 FCR7
N N
Yes M 9.54 16.99 140 10.32 18.40 78
SD 3.61 7.13 3.77 7.55
No M 9.19 16.05 106 8.96 15.74 168
SD 3.72 6.95 3.53 6.67
F 0.57 1.09 7.60 7.75
p 0.45 0.30 0.006 0.006
Humphris et al. Health and Quality of Life Outcomes  (2018) 16:30 Page 8 of 12
Table 7 IRT (2 parameter model) Summary results showing
discriminability (‘discrim’) and difficulty (‘diff’, i.e. location or
severity) coefficients
Coeff. SE z P
fcr1
Discrim 3.99 .451 8.86 0.000
Diff
>=2 −1.03 .108 −9.53 0.000
>=3 .05 .080 0.65 0.517
>=4 1.27 .116 10.93 0.000
=5 1.90 .154 12.38 0.000
fcr2
Discrim 5.23 .667 7.84 0.000
Diff
>=2 −.72 .091 −7.95 0.000
>=3 .39 .080 4.92 0.000
>=4 1.17 .108 10.82 0.000
=5 2.21 .180 12.26 0.000
fcr3
Discrim 5.12 .689 7.43 0.000
Diff
>=2 −1.30 .119 −10.93 0.000
>=3 −.26 .080 −3.27 0.001
>=4 1.03 .102 10.08 0.000
=5 2.07 .164 12.62 0.000
fcr4
Discrim 4.18 .515 8.12 0.000
Diff
>=2 −.03 .080 −0.41 0.682
>=3 .52 .086 6.09 0.000
>=4 1.45 .126 11.52 0.000
=5 2.28 .197 11.58 0.000
fcr5
Discrim 2.47 .283 8.74 0.000
Diff
>=2 −.27 .095 −2.87 0.004
>=3 .61 .103 5.95 0.000
>=4 2.32 .224 10.34 0.000
=5 3.36 .500 6.73 0.000
fcr6
Discrim .927 .141 6.56 0.000
Diff
>=2 −1.85 .306 −6.05 0.000
>=3 −.51 .171 −2.99 0.003
>=4 1.65 .277 5.98 0.000
=5 3.47 .544 6.38 0.000
Table 7 IRT (2 parameter model) Summary results showing
discriminability (‘discrim’) and difficulty (‘diff’, i.e. location or
severity) coefficients (Continued)
Coeff. SE z P
fcr7
Discrim 2.70 .262 10.30 0.000
Diff
>= 1 −.94 .114 −8.30 0.000
>= 2 −.22 .089 −2.51 0.012
>= 3 .20 .088 2.28 0.023
>= 4 .68 .100 6.82 0.000
>= 5 .99 .113 8.75 0.000
>= 6 1.26 .128 9.87 0.000
>= 7 1.58 .147 10.73 0.000
>= 8 1.73 .156 11.07 0.000
>= 9 2.39 .220 10.89 0.000
=10 2.68 .268 9.98 0.000
a
b
Fig. 3 IRT Test Information Curves for total scale scores (a) FCR4 (b)
FCR7 with ±1.96 Theta values marked with solid line to show the 95%
proportion of sample and corresponding upper and lower bound scale
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to admit to and therefore attenuating a possible strong
correlation.
Influence of past treatment (Rx and CRx)
The small positive associations between FCR and the
two principal modes of treatment (other than surgery)
namely: radiotherapy and chemotherapy were detected.
The association between chemotherapy and FCR was
significant and matches a previous meta-analysis [19].
The measures would appear to be able to reflect reliable
but small effects.
Psychometric properties IRT
The Item Response Theory results concentrated on each
of the items that compose the FCR4 and FCR7 scales in
detail. The discrimination and difficulty levels across the
items and categories were virtually all statistically signifi-
cant. Of interest is the strength of discriminability of the
FCR4 items which all attained a substantial level of 4.
The other three items that are added to FCR7 do not at-
tain such high levels but it can be argued that the longer
scale is attempting to assess a broader concept of FCR.
The advantage of the additional three items to the FCR4
is shown in the wider coverage of difficulty (or location)
that the 7 items provide (Category Characteristic Curves
in Additional file 2, especially for item ‘fcrq6’). This is
one of the first presentations of FCR short measures
adopting a two parameter IRT model. We argue that
there is good evidence to support the assumption of uni-
dimensionality from the EFA, however the local inde-
pendence assumption is a matter of judgement from
assessing the uniqueness of the item wording. This as-
pect may require additional attention in future studies.
Choice of version: FCR4 or FCR7?
The selection of FCR assessment, whether focussing on
these brief measures or others, is dependent on a variety of
factors. These will include preference for wording, time al-
located for patient profiling and purpose of study or service
function. From a psychometric perspective there is little to
choose between the FCR4 and FCR7. If the interest of the
user is to identify patients, say for research purposes, who
report no recurrence fears (so called ‘zero’-scorers) then the
FCR7 is again the preference as the respondent has mul-
tiple opportunities to confirm that they are not concerned.
A mobile phone application has been developed for routine
use for participants involved in research studies. Recom-
mended guidelines were adhered to [32]. If the user wishes
to assess repeatedly over a relatively short duration then
the FCR4 would be indicated as the respondent burden is
less. There is no meaningful difference in the reliability co-
efficients’ magnitude between the 2 versions. In addition,
classical validity evidence that has so far been presented is
consistent across versions.
The IRT evidence shows an interesting phenomenon.
The additional information provided by the technique high-
lights that the FCR7, in addition to assessing aspects of fear
and anxiety as the FCR4 does also includes two more cog-
nitive aspects (i.e. intrusions) and a coping strategy (behav-
ioural checking). A recent comment has highlighted that
some assessments of FCR are clearly designed to assess in-
tensity of fear such as the FCRI-Severity subscale (9 items),
whereas the CAR-Q includes 3 aspects of clinical symp-
toms that Lebel et al. [33] have argued are indicative of clin-
ical levels of FCR [34]. Our position would be that the
FCR4 is a quick screen for fear itself of FCR, whereas the
FCR7 would function as a possible indicator of 3 of the
clinical issues recommended for assessment that could trig-
ger early intervention [35]. We would encourage additional
item development if the researcher / clinician wished to
adopt a measure to locate clinical FCR. The 42 item Fear of
Cancer Recurrence Inventory (FCRI) would be a suitable
assessment for individuals to complete should their score
attain a level at the 90th percentile or higher. It is noted
that this has already been translated successfully into a
number of major languages [5, 36, 37].
Limitations and strengths
The assessment of FCR has been clarified with a consen-
sus definition now available [33]. These two brief scales
are limited to recurrence and are not suitable to assess
fear of progression of cancer. We are currently developing
a parallel version for the additional component described
in the definition. Sample size, in the current study, for the
colorectal cancer patients was low, however their inclu-
sion provided some evidence that the discrepancy in the
measures across the two sites was not appreciative, sup-
porting the view that separate FCR scales for each cancer
site is unwarranted. Further structural testing is required.
The sample of patients collected with breast and colorec-
tal cancer was not necessarily representative of patients
with these two conditions due to patients being with-
drawn by their clinical teams for further medical investiga-
tions. However the efficient use of IRT evaluation has
been described with a small clinical sample comparing
three common depression instruments [38]. These brief
measures we believe are faithful to the position adopted
by Costa who recommended clear and brief instrumenta-
tion for FCR [6]. The FCR4 and FCR7 are measures com-
prising items from four other FCR measures. Therefore
the user of the FCR4 or FCR7 will be able to make refer-
ence of discrete items directly to the other studies of re-
currence fears who report details of the identical items.
Two further issues are raised for consideration. Psycho-
metric developments in assessing FCR are encouraging and
becoming more sophisticated. The use of alternative models
such as IRT (as opposed to classical psychometric theory
[27]) hold promise to further improve our understanding of
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the constructed assessments. There are some notable exam-
ples of IRT applied to FCR measures [7, 39]. Assumptions
applied to IRT models tend to be more demanding and re-
quire large samples to derive precision of estimates, espe-
cially when random mixed models are applied. The ‘high N’
requirement would also apply to structural equation models
(SEM). The SEM approach is able to explicitly test assump-
tions of measurement principles, within the items that com-
pose the scale (e.g. correlated residuals), as well as construct
validation with detailed examination of associated constructs
(e.g. cross-construct loadings). As raised previously Simo-
nelli criticises the preponderance of single point investiga-
tions and lack of cross-cultural validity [3]. We would
recommend that investigators consider how changes in FCR
might be assessed in addition to concentration on the
‘steady-state’ FCR estimation. Finally we are aware that some
patients rate their FCR as effectively zero. The construct of
FCR is conceptually different to either anxiety or depression.
The more traditional assessments of negative mental state
concentrate on the higher levels. For FCR this would not be
the case. Patients who have zero scores on FCR have either
misunderstood the measure’s instructions and rating
scheme, avoiding exposure to rating the construct itself
(through denial for example) or are genuinely unfearful of
the possibility of cancer return. The consequences of the
‘zero-scorer’ are unknown in terms of health behaviour, out-
patients visits or self-checking for a recurrence.
Conclusion
The FCR4 and FCR7 are brief measures of FCR that are de-
signed to be easy, low burden scales for use in clinical set-
tings and research enquiries. Some psychometric qualities
are supportive of their internal consistency and evidence
for validity. Additional research to extend the background
information about these scales to assist interpretation are
required and warrant investigation.
Additional files
Additional file 1: FCR7 for copy of Scale. (DOCX 114 kb)
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